Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC

The goal of this clinical trial is to investigate the efficacy, safety and tolerability of PD-1/CTLA-4 inhibitor (Cadonilimab) combination with chemotherapy as first-line treatment for PD-L1 negative advanced non small cell lung cancer patients. And also explore the potential biomarkers for predicting the efficacy of PD-1/CTLA-4 inhibitor for advanced non small cell lung cancer.

Trial Details

NCT ID
NCT06424821
Phase
PHASE2
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Cadonilimab
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Ningbo, Zhejiang, China|29.87819,121.54945

Key Eligibility Criteria

  • Written informed consent must be obtained before implementing any trial-related procedures;
  • Aged 18-80 years;
  • Expected survival of more than 3 months;
  • The investigator confirms the presence of at least one measurable lesion according to RECIST 1.1 criteria;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →